FDA approves Drug Relief neurostimulation device for treating symptoms of opioid withdrawal.- DyAnsys Inc.

DyAnsys Inc. announced that the FDA has cleared its auricular neurostimulation device, Drug Relief, to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics. Drug Relief is available now for providers to prescribe for use during opioid detoxification. This wearable device sends electrical pulses through tiny needles inserted in the ear to alleviate symptoms such as anxiety, agitation, depression, nausea, opiate cravings and more.

Drug Relief is a percutaneous electrical nerve field stimulator designed to administer auricular neurostimulation treatment over 120 hours. The non-addictive treatment allows for continuous nerve stimulation over five days while offering the patient a high degree of comfort and mobility. According to providers, patients may see a reduction in the symptoms of opioid withdrawal within 30 to 60 minutes of beginning treatment. The device eases the process of detoxification, which is the first step in a comprehensive rehabilitation program.

The objective is to ease symptoms while opioids are cleared from a patient's system. It can be used to help stabilize a patient during the early stages of withdrawal without side effects. Stabilization is a necessary first step before treating the patient with medication-assisted therapies like naltrexone.